Close Menu

NEW YORK – The US Food and Drug Administration granted accelerated approval on Friday to trastuzumab deruxtecan (Daiichi Sankyo's Enhertu, DS-8201) for the treatment of unresectable or metastatic HER2-positive breast cancer that had been previously treated with anti-HER2 regimens. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.